SYNGENTA AG Form 6-K February 06, 2013

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For the month of February 2013

Commission File Number: 001-15152

SYNGENTA AG (Translation of registrant's name into English)

Schwarzwaldallee 215 4058 Basel Switzerland (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form X Form 20-F 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes No X

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes No X

Indicate by check mark whether by furnishing the information contained in this Form, the Registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

Yes No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

Re: SYNGENTA AG Disclosure: 1 - "2012 Full Year Results: Continued sales momentum and record earnings" 2 - "Syngenta Board proposes to elect two new directors at AGM" 3 - "Syngenta to expand corn seed production capacity in Formosa, Brazil"

Herewith we furnish press releases related to Syngenta AG. The full text of the press releases are the following:

###

Item 1

Syngenta International AG	Media contacts:	Analyst/Investor contacts:		
Media Office CH-4002 Basel Switzerland Tel: +41 61 323 2323 Fax: +41 61 323 2424	Paul Barrett Switzerland +41 61 323 2323	Jennifer Gough Switzerland +41 61 323 5059 USA +1 202 737 6521		
www.syngenta.com	Daniel Braxton Switzerland +41 61 323 2323	Lars Oestergaard Switzerland +41 61 323 6793 USA +1 202 737 6520		

Basel, Switzerland, February 6, 2013

2012 Full Year Results

Continued sales momentum and record earnings

•	Sales \$14.2 billion, up 7 percent; up 10 percent at constant exchange rates (CER)1
	- strong fourth quarter in North and Latin America
	- double digit Seeds growth in all regions (CER)
•	EBITDA up 17 percent at CER
•	Net income \$1.9 billion, up 17 percent
•	Earnings per share2 \$22.30, up 15 percent
•	Free cash flow before record level of acquisitions: \$0.9 billion
•	Proposed dividend increased by 19 percent to CHF 9.50

	Reported Financial Highlights					
			Actual	CER1		
	\$2012m	\$2011m	%	%		
Sales	14,202	13,268	+ 7	+ 10		
Operating income	2,292	2,051	+ 12			
Net income3	1,872	1,599	+ 17			
EBITDA	3,150	2,905	+ 8	+17		
Earnings per share2	\$22.30	\$19.36	+ 15			

1	Growth at constant exchange rates
2	Excluding restructuring and impairment; EPS on a fully-diluted basis.
3	Net income to shareholders of Syngenta AG (equivalent to diluted earnings per share of \$20.32).

Mike Mack, Chief Executive Officer, said:

"In 2012, crop prices rose sharply as adverse weather conditions in several regions resulted in significant production shortfalls, once again highlighting the fragility of global supply. Growers in the affected regions had to adapt quickly in terms of planting and investment decisions, while also dealing with ongoing challenges such as weed and insect resistance. The strong growth in Syngenta's sales reflected our flexibility in providing solutions across crops and, increasingly, in addressing agronomic challenges through our integrated offers. These are proving their worth in developed and emerging regions alike, contributing to growth rates of eight percent and 11 percent respectively.

"Since the announcement of our new strategy two years ago, we have been driving the development of our portfolio by crop. The results already achieved in the field and the potential for new integrated offers have enabled us to increase target sales for our eight strategic crops to \$25 billion by 2020. In addition, last year we made a number of acquisitions to secure new technologies. We were able to do so while maintaining a strong balance sheet as evidenced by the proposal of another substantial increase in the dividend."

Financial highlights 2012

Sales \$14.2 billion

Sales increased by ten percent at constant exchange rates. Sales volume increased by seven percent and prices were three percent higher. Reported sales growth was seven percent owing to the appreciation of the dollar against most currencies.

EBITDA \$3.2 billion

At constant exchange rates EBITDA increased by 17 percent and the EBITDA margin (CER) was 23.2 percent (2011: 21.9 percent). The increase in profitability reflects the operational leverage from volume growth, price increases and the recognition of an additional \$200 million of trait royalty from DuPont Pioneer, accompanied by cost savings largely from the integrated business model of \$198 million. These together more than offset the impact of higher raw material costs and a net \$80 million charge for the settlement of US litigation relating to the herbicide atrazine.

The reported margin was 22.2 percent. The negative impact of currency was \$235 million, or 100 basis points.

Net financial expense and taxation

Net financial expense of \$147 million was slightly lower than in 2011 (\$165 million). The tax rate before restructuring and impairment was 15 percent.

Net income \$1.9 billion

Net income including restructuring and impairment was up 17 percent. Earnings per share, excluding restructuring and impairment, increased by 15 percent to \$22.30.

Cash flow and balance sheet

Free cash flow before acquisitions totaled \$924 million. Average trade working capital as a percentage of sales was further reduced to 35 percent from 37 percent in 2011. Fixed capital expenditure including intangibles was \$679 million (2011: \$575 million) reflecting increased investment to meet growing demand, notably in the emerging markets. Acquisition spending reached \$654 million, with opportunities to acquire new technologies and to expand

seeds production capability. Cash flow return on investment at 15 percent again exceeded the 12 percent target. The ratio of net debt to equity was 20 percent (2011: 15 percent).

Syngenta – February 6, 2013/ 2 of 42

Dividend and share repurchase

The total cash return to shareholders in 2012 was \$795 million. The dividend was raised by 14 percent, or 13 percent in US dollars, to give a total dividend payout of \$791 million. Share repurchases amounted to \$4 million: the primary focus is on the dividend and in 2012 there was significant expenditure on acquisitions.

In the light of continuing strong free cash flow generation, the Board of Directors will propose to the AGM on April 23, 2013 an increase in the dividend to CHF 9.50 per share from CHF 8.00 in 2011. This represents an increase of 19 percent in Swiss francs and around 21 percent in US dollars at end January exchange rates. As in previous years, the company retains the flexibility to execute tactical share buybacks.

Business Highlights 2012

	Full Year		Growth		4th Quarter		Growth	
			Actual	CER			Actual	CER
	\$2012m	\$2011m	%	%	\$2012m	\$2011m	%	%
Europe, Africa & Middle								
East	3,974	3,982	-	+ 6	387	414	- 7	- 3
North America	3,931	3,273	+ 20	+ 21	690	538	+ 28	+ 28
Latin America	3,713	3,305	+ 12	+ 13	1,556	1,324	+ 18	+ 17
Asia Pacific	1,827	1,887	- 3	-	432	443	- 3	- 1
Total regional sales	13,445	12,447	+ 8	+ 11	3,065	2,719	+ 13	+ 13
Lawn and Garden(1)	757	821	- 8	- 6	174	184	- 6	- 5
Group sales	14,202	13,268	+ 7	+ 10	3,239	2,903	+ 12	+ 12

Regional sales performance

•	Sales \$13.4 billion, up 11%(2)
•	Volume +8%, price +3%
•	EBITDA \$3.0 billion (2011: \$2.8 billion)
•	EBITDA margin(2) 23.8% (2011: 22.5%)

Europe, Africa and the Middle East: Growth was broad-based with the strongest contributions to growth coming from the CIS and South East Europe, where commercial integration is driving clear gains in scale and in customer recognition of our portfolio. Seeds sales were in addition driven by the substitution of corn and sunflower for lost winter cereal crops. France also registered a strong full year performance led by growth in fungicides. Sales in southern Europe were lower owing to dry weather as well as the economic downturn.

(1) (2) Including impact of divestments At constant exchange rates

Syngenta - February 6, 2013/3 of 42

North America had an excellent year across the business. The expansion of our corn technology resulted in good underlying seeds sales growth which was augmented by licensing revenue. A warm winter and an early planting season favored the use of herbicides and insecticides, with further momentum coming from the ongoing success of our weed and insect resistance management programs. This more than offset a reduction in third quarter fungicide applications due to the summer drought. Low channel inventories and strong demand in advance of the 2013 season led to an acceleration of growth in the fourth quarter.

Latin America staged a strong recovery from drought conditions which reduced sales in the first quarter. High soybean prices encouraged increases in acreage and investment. The development of second season corn is favoring technology adoption in both crop protection and seeds. The traction resulting from the early integration of our commercial teams in Brazil has added impetus to the growth in our seeds portfolio, with share gains in both corn and soybean. The need to boost sugar cane productivity was reflected in strong growth in herbicide sales and the identification of new opportunities in seedlings and young plants.

Asia Pacific: Sales excluding the impact of range rationalization and registrations increased five percent. China and South East Asia both reported double digit growth with expansion in corn and the roll-out of DURIVO® insecticides. Growth in South Asia was more moderate owing to an erratic monsoon and to the product phase-outs which also affected sales in Japan. Sales in Australasia were lower owing to early floods followed by exceptionally hot and dry conditions in the second half of the year.

Lawn and Garden performance

•	Sales \$757 million, 6% lower(1)
•	EBITDA \$103 million (2011: \$103 million)
•	EBITDA margin(1) 13.9% (2011: 12.5%)

Excluding the impact of acquisitions and divestments, sales were broadly flat. While low consumer spending and cautious retailer behavior continued to affect many markets, we made significant progress in simplifying the business and focusing on high value chemistry and genetics. This included the divestment of some lower margin businesses including Fafard growing media, which in June was sold to Sun Gro Horticulture Canada Ltd., with whom we continue to collaborate in order to include growing media in our integrated offers. In November we announced that Griffin Greenhouse Supplies, Inc., will acquire the Syngenta Horticultural Services flowers distribution and brokerage business. The acquisition of the DuPont Professional Products insecticide business will augment our portfolio of chemical controls with the established Advion® and Acelepryn® brands.

Capacity expansion

In Argentina, Syngenta announced a \$50 million investment to build a new processing plant for corn and sunflower seeds. In Brazil, the company plans to quadruple the capacity of its Formosa corn processing plant. Syngenta has also signed a letter of intent to invest up to \$85 million in the construction of a hybrid seed and crop protection facility in Krasnodarskiy Krai in Russia.

At constant exchange rates

(1)

Acquisitions

The DuPont Professional Products business (see under Lawn and Garden) was acquired for \$125 million and consolidated with effect from October 2012.

In September Syngenta agreed to pay \$86 million, with additional deferred payments of up to \$27 million, for Pasteuria Bioscience Inc. The naturally occurring soil bacteria Pasteuria spp will be used to develop cost-effective nematicides with a novel mode of action.

In November Syngenta commenced a tender offer valued at €403 million for the Belgian company Devgen, a global leader in hybrid rice and RNAi technology. By January 18, 2013, 98.32 percent of the total number of shares in Devgen had been tendered; the remaining shares will be acquired through a squeeze-out. The acquisition, which was consolidated from December 2012, will reinforce Syngenta's leading position in the global rice market and will enable the combination of RNAi-based crop applications with our broad crop protection portfolio.

Also in November, Syngenta announced the acquisition of Sunfield Seeds, a US-based provider of sunflower seeds production and processing services. The acquisition will strengthen our sunflower supply capability in support of future growth.

New partnerships: Syngenta and Novozymes signed two global agreements in 2012. Firstly, the two companies will jointly commercialize the Novozymes technology JumpStart®, a seed-applied biological which increases phosphate uptake in the soil. A second marketing and distribution agreement relates to Taegro®, a fermented biological fungicide which offers growers broad-spectrum disease control at low application rates.

Under a barley breeding agreement with Intergrain, Syngenta has gained exclusive commercialization rights for all new barley varieties, and exclusive rights to commercialize existing Intergrain varieties outside Australia.

Crop pipelines: In September, Syngenta upgraded its sales target for its eight key crops to \$25 billion by 2020. This compares with a previous target of over \$22 billion post-2015. The upgrade followed strategic updates covering four of the crops: Cereals, Corn, Rice and Vegetables. The sales target comprises growth in the existing portfolio and the launch of new products, with an increasing emphasis on integrated offers.

Performance metrics: The performance of our portfolio and the development of our integrated offers enabled us to gain further market share in 2012. This supports our confidence in achieving the target of an annual average 0.5 percent market share gain across the combined business over the next five years. In 2012 the group EBITDA margin of 22.2 percent was within the target range of 22-24 percent set for 2015. This achievement is against a backdrop of currency and raw material headwinds as well as ongoing investments in growth. Cash Flow Return on Investment at 15 percent was significantly ahead of the targeted rate of over 12 percent. These results are reflected in the proposed dividend increase, in line with our strategy of returning cash to shareholders.

Outlook

Mike Mack, Chief Executive Officer, said:

"Our confidence in the coming season is reinforced by the fourth quarter business strength, notably in North and Latin America, as well as robust commodity crop prices. In 2013 we look forward to further business momentum driven by our innovative offers and a commercial organization which is now fully integrated in all territories. We also expect to generate significant free cash flow, while continuing to invest in the realization of our crop-based pipelines and in the ongoing expansion of our commercial footprint, notably in the emerging markets."

Syngenta – February 6, 2013/ 5 of 42

	Full Y	'ear	Grow	'th	4th Qu	arter	Grov	vth
Crop Protection	2012	2011	Actual	CER	2012	2011	Actual	CER
by product line	\$m	\$m	%	%	\$m	\$m	%	%
Selective herbicides	2,939	2,617	+12	+ 15	589	417	+ 41	+ 42
Non-selective herbicides	1,246	1,117	+ 12	+ 14	298	231	+ 29	+ 29
Fungicides	3,044	2,998	+ 2	+ 4	758	704	+ 8	+ 8
Insecticides	1,841	1,790	+ 3	+ 6	513	496	+ 4	+ 4
Seed care	1,107	1,018	+ 9	+ 12	320	332	- 3	- 3
Other crop protection	141	137	+ 2	+ 5	36	39	- 10	- 10
Total	10,318	9,677	+ 7	+ 9	2,514	2,219	+ 13	+ 14

Crop Protection

Selective herbicides: major brands AXIAL®, CALLISTO® family, DUAL®/BICEP® MAGNUM, FUSILADE®MAX, TOPIK®

AXIAL® on cereals registered double digit growth in all regions. The largest contribution came from Canada, where increased acreage coincided with low channel inventories at the start of the year. In corn, the CALLISTO® family and DUAL®/BICEP grew strongly in the USA driven by their success in managing resistant weeds as well as high corn prices. Adoption of both products on sugar cane in Brazil, where they form part of integrated agronomic protocols, is accelerating rapidly.

Non-selective herbicides: major brands GRAMOXONE®, TOUCHDOWN®

GRAMOXONE® showed good growth in Latin America and the USA, where it was used as an alternative to glyphosate in areas of weed resistance. Sales in the developed markets of Asia Pacific were lower, partly due to non-renewal of the registration in South Korea. TOUCHDOWN® sales grew strongly notably in the Americas reflecting a high level of demand on corn and soybean and a shortage of generic supply.

Fungicides: major brands ALTO®, AMISTAR®, BRAVO®, REVUS®, RIDOMIL GOLD®, SCORE®, TILT®, UNIX®

Fungicide sales progressed despite drought in Latin America in the first quarter and in the USA throughout the summer. The largest product AMISTAR® continues to expand: volume growth was driven by our offer comprising multiple mixtures and formulations adapted by crop and geography, and pricing remained robust. Sales of REVUS® for vegetables, vines and potatoes were up by 25 percent in Europe, its main market. In November, the European Union granted full approval for isopyrazam, which will represent a major step forward in the control of a wide variety of damaging fungal diseases.

Insecticides: major brands ACTARA®, DURIVO®, FORCE®, KARATE®, PROCLAIM®, VERTIMEC®

Excluding the impact of range rationalization, sales were up 10 percent led by the Americas. In the USA, a mild winter and dry weather throughout the corn belt created heavy early insect pressure. In addition, grower awareness of corn rootworm resistance and of the benefits of soil-based insecticides increased, with North American sales of FORCE® more than doubling as a result. Latin American growth was driven by technology adoption, with the strongest contributions coming from ACTARA® and DURIVO®.

Seed care: major brands AVICTA®, CRUISER®, DIVIDEND®, CELEST/MAXIM®, VIBRANCETM

Global growth was led by CRUISER® and CELEST/MAXIM®. Ongoing technology adoption drove a particularly strong performance in the emerging markets, where sales were up by over 20 percent. In Latin America the nematicide AVICTA® also showed strong growth. VIBRANCETM, a new compound which delivers enhanced root health as well as controlling a wide range of diseases, was successfully launched in North America.

	Full Ye	ear	Grow	'th	4th Qua	arter	Grow	rth
Crop Protection	2012	2011	Actual	CER	2012	2011	Actual	CER
by region	\$m	\$m	%	%	\$m	\$m	%	%
Europe, Africa, Mid.								
East	2,910	2,958	- 2	+ 5	325	354	- 8	- 5
North America	2,577	2,158	+ 19	+ 20	422	286	+ 47	+ 47
Latin America	3,261	2,907	+ 12	+ 13	1,411	1,208	+ 17	+ 17
Asia Pacific	1,570	1,654	- 5	- 2	356	371	- 4	- 3
Total	10,318	9,677	+ 7	+9	2,514	2,219	+ 13	+ 14

Seeds

	Full Y	<i>ear</i>	Grow	rth	4th Qua	arter	Grow	th
Seeds	2012	2011	Actual	CER	2012	2011	Actual	CER
by product line	\$m	\$m	%	%	\$m	\$m	%	%
Corn and Soybean	1,836	1,471	+ 25	+ 26	386	334	+ 15	+ 15
Diverse Field Crops	719	676	+ 6	+ 11	66	77	- 14	- 12
Vegetables	682	703	- 3	+ 1	148	131	+ 14	+ 15
Total	3,237	2,850	+ 14	+ 16	600	542	+ 11	+ 11

Corn and Soybean: major brands AGRISURE®, GARST®, GOLDEN HARVEST®, NK®

Sales were up strongly in all regions driven by corn worldwide and by soybean in Latin America. North American sales were augmented by additional corn trait royalty income of around \$200 million received in the first half; excluding this amount global corn sales were up 15 percent, with a positive customer response to our broad technology offer. In Latin America corn growth was driven by the expansion of the second season in Brazil, where sales were up by more than 30 percent helped by the launch of new trait combinations. Increases in soybean acreage for the 2012/13 season have been accompanied by strong demand for our leading varieties such as V-Max. The integrated PLENUS® offer is growing well in Argentina where it now accounts for around three quarters of the portfolio.

Diverse Field Crops: major brands NK® oilseeds, HILLESHÖG® sugar beet

Growth was led by sunflower in Eastern Europe where we are capturing value from the expansion of our leading conventional and high oleic hybrids. In North America, growth in sunflower and cereals more than offset the disposal of the sorghum business. Hybrid barley is starting to make a significant contribution in major Western European countries, alongside growth in the existing wheat business.

Syngenta – February 6, 2013/7 of 42

Vegetables: major brands DULCINEA®, ROGERS®, S&G®

There was an upturn in the fourth quarter which offset the earlier impact of a difficult economic environment. In North America, the processing market has recovered from a period of oversupply and fresh produce sales are benefiting from strong demand for miniature watermelons. In Mexico and Iberia, Zeraim's leading tomato and pepper varieties are driving sales.

	Full Year		Growth		4th Quarter		Grow	rth
	2012	2011	Actual	CER	2012	2011	Actual	CER
Seeds by region	\$m	\$m	%	%	\$m	\$m	%	%
Europe, Africa, Mid.								
East	1,101	1,063	+ 4	+ 10	83	86	- 3	- 1
North America	1,398	1,142	+ 22	+ 22	292	266	+ 10	+ 9
Latin America	479	409	+ 17	+ 18	148	118	+ 26	+ 26
Asia Pacific	259	236	+ 10	+ 16	77	72	+ 6	+ 9
Total	3,237	2,850	+ 14	+ 16	600	542	+ 11	+ 11

Announcements and Meetings

2012 Annual Report publication	March 13, 2013
First quarter trading statement	April 18, 2013
AGM	April 23, 2013
Crop update	July 9-11, 2013
First half results	July 24, 2013
Third quarter trading statement	October 17, 2013
Crop update	December 4-6, 2013

Syngenta is one of the world's leading companies with more than 27,000 employees in over 90 countries dedicated to our purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve health and quality of life. For more information about us please go to www.syngenta.com.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such statements may be sub to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract there for.

Syngenta – February 6, 2013/8 of 42

Syngenta Group

Condensed Consolidated Financial Statements

The following condensed consolidated financial statements and notes thereto, which do not themselves contain all of the information that IFRS would require for a complete set of financial statements, are based on and are consistent with Syngenta's consolidated financial statements prepared in accordance with International Financial Reporting Standards (IFRS) as described in Note 1.

Condensed Consolidated Income Statement

For the year ended December 31,				
(\$m, except share and per share amounts)	2012		2011	
Sales	14,202	13,26	58	
Cost of goods sold	(7,218) (6,78	6)	
Gross profit	6,984	6,482	2	
Marketing and distribution	(2,418) (2,38) (7	
Research and development	(1,253) (1,19	1)	
General and administrative:				
Restructuring	(233) (307)	
Divestment gains/(losses)	(25) 76		
Other general and administrative	(763) (622)	
Operating income	2,292	2,051	l	
Income from associates and joint ventures	7	15		
Financial expense, net	(147) (165)	
Income before taxes	2,152	1,901	l	
Income tax expense	(277) (301)	
Net income	1,875	1,600)	
Attributable to:				
Syngenta AG shareholders	1,872	1,599)	
Non-controlling interests	3	1		
Net income	1,875	1,600)	
Earnings per share (\$):				
Basic	20.43	17.40)	
Diluted	20.32	17.31	l	
Weighted average number of shares:				
Basic	91,644,190	91,89	92,275	
Diluted	92,132,922	92,38	33,611	

All activities were in respect of continuing operations.

Syngenta – February 6, 2013/9 of 42

Condensed Consolidated Statement of Comprehensive Income

For the year ended December 31,				
(\$m)	201	2	20	11
Net income	1,875		1,600	
Components of other comprehensive income (OCI):				
Items that will not be reclassified to profit or loss:				
Actuarial gains/(losses) of defined benefit post-employment plans	(151)	(252)
Income tax relating to items that will not be reclassified to profit or loss	31		71	
	(120)	(181)
Items that may be reclassified subsequently to profit or loss:				
Unrealized gains/(losses) on available-for-sale financial assets	(1)	3	
Gains/(losses) on derivatives designated as cash flow and net investment hedges	108		(150)
Currency translation effects	86		(186)
Income tax relating to items that may be reclassified subsequently to profit or loss	(22)	(14)
	171		(347)
Total comprehensive income	1,926		1,072	
Attributable to:				
Syngenta AG shareholders	1,924		1,072	
Non-controlling interests	2		-	
Total comprehensive income	1,926		1,072	

All activities were in respect of continuing operations.

Syngenta – February 6, 2013/ 10 of 42

Condensed Consolidated Balance Sheet

Non- Initial Initial <thinitial< th=""> <thinitial< th=""> <thinit< th=""><th>At December 31, (\$m)</th><th>2012</th><th>2011</th></thinit<></thinitial<></thinitial<>	At December 31, (\$m)	2012	2011
Current assets: 1.599 1.666 Trade receivables 3,191 2,736 Other accounts receivable 932 690 Inventories 4,734 4,190 Derivative and other financial assets 251 269 Other current assets 257 199 Total current assets 10,964 9,750 Non-current assets: 10,964 9,750 Property, plant and equipment 3,193 3,025 Intangible assets 3,501 2,869 Deferred tax assets 1,075 930 Financial and other non-current assets 668 667 Total and equipy 17,241 Liabilities and equity 17,241 Liabilities and equity 11,724 Liabilities 104 Current liabilities: 1,048 (955 1 Current liabilities 1,160 (1,028 1 Other current liabilities (236 (232 2 Outer current liabilities (64,27 (5,643 1 Non-c		2012	2011
Cash and cash equivalents 1,599 1,666 Trade receivables 3,191 2,736 Other accounts receivable 932 690 Inventories 4,734 4,190 Derivative and other financial assets 251 269 Other current assets 257 199 Total current assets 10,964 9,750 Non-current assets 3,193 3,025 Intangible assets 3,501 2,869 Deferred tax assets 1,075 930 Financial and other non-current assets 668 667 Total non-current assets 8,437 7,491 Total assets 19,401 17,241 Liabilities and equip 11,075 930 Trade accounts payable (3,409 (2,881 Current liabilities 11,014 (955 Income taxes payable (574 (547 Other current liabilities (1,160 (1,028 Provisions (236 (232) Total current liabilities (2,514 (2,374 Income taxes payable (2,643			
Trade receivables 3,191 2,736 Other accounts receivable 932 690 Inventories 4,734 4,190 Derivative and other financial assets 251 269 Other current assets 257 199 Total current assets 10,964 9,750 Non-current assets 3,193 3,025 Intangible assets 3,501 2,869 Deferred tax assets 1,075 930 Financial and other non-current assets 668 667 Total anon-current assets 8,437 7,491 Total assets 19,401 17,241 Liabilities: Urrent financial debt and other financial liabilities (1,048 (955 Current financial debt and other financial liabilities (1,160 (1,028) Provisions (236 (232) Total current liabilities: (574 (5643) Income taxes payable (2,514 (2,374) Deferred tax liabilities (2,514 (2,374) Deferred tax liabilities (2,514 (2,374 <t< td=""><td></td><td>1,599</td><td>1,666</td></t<>		1,599	1,666
Other accounts receivable 932 690 Inventories 4,734 4,190 Derivative and other financial assets 251 269 Other current assets 257 199 Total current assets 10,964 9,750 Non-current assets 10,964 9,750 Non-current assets 3,193 3,025 Intangible assets 3,501 2,869 Deferred tax assets 1,075 930 Financial and other non-current assets 668 667 Total assets 19,401 17,241 Liabilities and equity 10,401 17,241 Liabilities and equity 10,409 12,881 Current liabilities (1,048 (955 Income taxes payable (547) Other current liabilities (2,364) Income taxes payable (547) Other current liabilities: (2,364) Income taxes payable (547) Other current liabilities: (2,364	1	,	,
Derivative and other financial assets 251 269 Other current assets 257 199 Total current assets 10,964 9,750 Non-current assets 10,964 9,750 Non-current assets 3,193 3,025 Intangible assets 3,501 2,869 Deferred tax assets 1,075 930 Financial and other non-current assets 668 667 Total non-current assets 19,401 17,241 Liabilities and equity 17,241 14bilities: Current financial debt and other financial liabilities (1,048) (2,881) Current financial debt and other financial liabilities (1,048) (955)) Income taxes payable (574) (547) (547) Other current liabilities (2,26) (2,22)) Total current liabilities (2,514) (2,374)) Provisions (863) (753)) Provisions (841) (968)) Total current liabilities	Other accounts receivable		690
Other current assets 257 199 Total current assets 10,964 9,750 Non-current assets:	Inventories	4,734	4,190
Total current assets 10,964 9,750 Non-current assets: 3,193 3,025 Intangible assets 3,501 2,869 Deferred tax assets 1,075 930 Financial and other non-current assets 668 667 Total non-current assets 8,437 7,491 Total assets 19,401 17,241 Liabilities and equity Current liabilities: V Trade accounts payable (3,409 (2,881 Current liabilities (1,048) (955 Income taxes payable (574 (547) Other current liabilities (1,160 (1,028) Provisions (2,236) (2,374) Non-current liabilities (6,427 (5,643) Non-current liabilities (2,374) (2,374) Deferred tax liabilities (4,015 (4,095) Total non-current liabilities (4,045 (4,045) Provisions (841 (968) Total non-current liabilities (10	Derivative and other financial assets	251	269
Non-current assets: 3,193 3,025 Intangible assets 3,501 2,869 Deferred tax assets 1,075 930 Financial and other non-current assets 668 667 Total non-current assets 8,437 7,491 Tota ano-current assets 19,401 17,241 Liabilities and equity 11,048 955 Current liabilities: (1,048 955 Tota counts payable (1,048 955 Current liabilities (1,160 (1,028 Provisions (236 (232 Total current liabilities (6,427 (5,643 Non-current liabilities (2,514 (2,514 Provisions (2,514 (2,374 Stat and other non-current liabilities (863 (753 Provisions (841 (968 (10,645 (9,733 Provisions (841 (968 (10,645 (9,738 (10,645 (9,738 (10,645 (9,738 (7,494 (10,645 (9,738 (10,645 <t< td=""><td>Other current assets</td><td>257</td><td>199</td></t<>	Other current assets	257	199
Property, plant and equipment 3,193 3,025 Intangible assets 3,501 2,869 Deferred tax assets 1,075 930 Financial and other non-current assets 668 667 Total non-current assets 8,437 7,491 Total assets 19,401 17,241 Liabilities and equity 19,401 17,241 Current liabilities: 1 1048 (955 Trade accounts payable (3,409 (2,881) Current financial debt and other financial liabilities (1,048 (955) Income taxes payable (574 (547) Other current liabilities (1,160 (1,028) Provisions (236 (232) Total current liabilities: (4,217 (5,643) Provisions (2,514 (2,374) Deferred tax liabilities (863 (753) Provisions (863 (753) Deferred tax liabilities (10,645 (9,738) Total non-current liabilities	Total current assets	10,964	9,750
Intargible assets 3,501 2,869 Deferred tax assets 1,075 930 Financial and other non-current assets 668 667 Total non-current assets 8,437 7,491 Total assets 19,401 17,241 Liabilities and equity Urrent liabilities: Vertex Trade accounts payable (3,409) (2,881) Current financial debt and other financial liabilities (1,048) (955) Income taxes payable (574) (547) Other current liabilities (1,160) (1,028) Provisions (236) (232) Total non-current liabilities (6,427) (5,643) Non-current liabilities: Vertex Vertex Financial debt and other non-current liabilities (2,514) (2,374) Deferred tax liabilities (863) (753) Provisions (841) (968) Total non-current liabilities (4,218) (4,095) Total non-current liabilities (10,05) (7,38) Provisions (8,745) (7,494) Notal inabilities (11)	Non-current assets:		
Deferred tax assets 1,075 930 Financial and other non-current assets 668 667 Total non-current assets 8,437 7,491 Total assets 19,401 17,241 Liabilities and equity 19,401 17,241 Current liabilities: 19,401 17,241 Trade accounts payable (3,409) (2,881) Current financial debt and other financial liabilities (1,048) (955) Income taxes payable (574) (547) Other current liabilities (1,160) (1,028) Provisions (236) (232)) Total current liabilities (6,427) (5,643)) Non-current liabilities (2,514) (2,374)) Provisions (2,514) (2,374)) Deferred tax liabilities (863) (753)) Provisions (841) (968)) Total non-current liabilities (4,218) (4,095)) Total liabilities (8,745) (7,494	Property, plant and equipment	3,193	3,025
Financial and other non-current assets 668 667 Total non-current assets 8,437 7,491 Total assets 19,401 17,241 Liabilities and equity 19,401 17,241 Current liabilities: 1 19,401 17,241 Trade accounts payable (3,409) (2,881) 1 Current financial debt and other financial liabilities (1,048) (955) 1 Income taxes payable (574) (547) 0 1 1 Other current liabilities (1,160) (1,028) 1 <td>Intangible assets</td> <td>3,501</td> <td>2,869</td>	Intangible assets	3,501	2,869
Total non-current assets 8,437 7,491 Total assets 19,401 17,241 Liabilities and equity 19,401 17,241 Current liabilities: 19,401 17,241 Trade accounts payable (3,409 (2,881) Current financial debt and other financial liabilities (1,048 (955) Income taxes payable (574 (547) Other current liabilities (1,160 (1,028) Provisions (236 (232) Total current liabilities (6,427 (5,643) Non-current liabilities (2,514 (2,374) Provisions (863 (753) Provisions (863 (753) Provisions (841 (968) Total non-current liabilities (10,645 (9,738) Provisions (10,645 (9,738) Equity: Italiabilities (10,645 (7,494) Equity: Ital equity (8,756 (7,503) <td>Deferred tax assets</td> <td>1,075</td> <td>930</td>	Deferred tax assets	1,075	930
Total assets 19,401 17,241 Liabilities and equity 17ade accounts payable 3,409 2,881 Trade accounts payable (3,409 (2,881) Current financial debt and other financial liabilities (1,048) (955) Income taxes payable (574) (547) Other current liabilities (1,160) (1,028) Provisions (236) (232) Total current liabilities (6,427) (5,643) Non-current liabilities: (2,514) (2,374) Provisions (2,514) (2,374) Deferred tax liabilities (2,514) (2,374) Provisions (863) (753) Provisions (841) (968) Total non-current liabilities (4,095)) Total non-current liabilities (10,645) (9,738) Equity:	Financial and other non-current assets	668	667
Liabilities and equity (3,409) (2,881) Current liabilities: (1,048) (955) Income taxes payable (574) (547) Other current liabilities (1,160) (1,028) Provisions (236) (232) Total current liabilities (6,427) (5,643) Non-current liabilities (2,514) (2,374) Deferred tax liabilities (863) (753) Provisions (841) (968) Total non-current liabilities (1,0645) (9,738) Equity: Shareholders' equity (8,745) (7,494) Non-controlling interests (11) (9) (10)	Total non-current assets	8,437	7,491
Current liabilities: Trade accounts payable (3,409) (2,881) Current financial debt and other financial liabilities (1,048) (955) Income taxes payable (574) (547) Other current liabilities (1,160) (1,028) Provisions (236) (232) Total current liabilities (6,427) (5,643) Non-current liabilities: (5,214) (2,374) Financial debt and other non-current liabilities (2,514) (2,374) Deferred tax liabilities (863) (753) Provisions (841) (968) Total non-current liabilities (10,645) (9,738) Equity: Shareholders' equity (8,745) (7,494) Non-controlling interests (11) (9) Total equity (8,756) (7,503)	Total assets	19,401	17,241
Current liabilities: Trade accounts payable (3,409) (2,881) Current financial debt and other financial liabilities (1,048) (955) Income taxes payable (574) (547) Other current liabilities (1,160) (1,028) Provisions (236) (232) Total current liabilities (6,427) (5,643) Non-current liabilities: (5,214) (2,374) Financial debt and other non-current liabilities (2,514) (2,374) Deferred tax liabilities (863) (753) Provisions (841) (968) Total non-current liabilities (10,645) (9,738) Equity: Shareholders' equity (8,745) (7,494) Non-controlling interests (11) (9) Total equity (8,756) (7,503)	Liabilities and equity		
Current financial debt and other financial liabilities (1,048) (955) Income taxes payable (574) (547) Other current liabilities (1,160) (1,028) Provisions (236) (232) Total current liabilities (6,427) (5,643) Non-current liabilities: (574) (2,514) Financial debt and other non-current liabilities (2,514) (2,374) Deferred tax liabilities (863) (753) Provisions (841) (968) Total non-current liabilities (1,0645) (9,738) Equity: (11) (9,749) Non-controlling interests (11) (9			
Income taxes payable (574) (547) Other current liabilities (1,160) (1,028) Provisions (236) (232) Total current liabilities (6,427) (5,643) Non-current liabilities: (5,544) (2,514) Financial debt and other non-current liabilities (2,514) (2,374) Deferred tax liabilities (863) (753) Provisions (841) (968) Total non-current liabilities (4,218) (4,095) Total liabilities (10,645) (9,738) Equity: Shareholders' equity (8,745) (7,494) Non-controlling interests (11) (9) Total equity (8,766) (7,503)	Trade accounts payable	(3,409)	(2,881)
Other current liabilities (1,160) (1,028) Provisions (236) (232) Total current liabilities (6,427) (5,643) Non-current liabilities: (2,514) (2,374) Deferred tax liabilities (863) (753) Provisions (841) (968) Total non-current liabilities (4,218) (4,095) Total liabilities (10,645) (9,738) Equity: (8,745) (7,494) Non-controlling interests (11) (9) Total equity (8,756) (7,503)	Current financial debt and other financial liabilities	(1,048)	(955)
Provisions (236) (232) Total current liabilities (6,427) (5,643) Non-current liabilities: (2,514) (2,374) Financial debt and other non-current liabilities (863) (753) Deferred tax liabilities (863) (753) Provisions (841) (968) Total non-current liabilities (4,218) (4,095) Total liabilities (10,645) (9,738) Equity: Shareholders' equity (8,745) (7,494) Non-controlling interests (11) (9) 1 Total equity (8,756) (7,503) 1	Income taxes payable	(574)	(547)
Total current liabilities (6,427) (5,643) Non-current liabilities: (2,514) (2,374) Financial debt and other non-current liabilities (863) (753) Deferred tax liabilities (863) (753) Provisions (841) (968) Total non-current liabilities (4,218) (4,095) Total liabilities (10,645) (9,738) Equity: Shareholders' equity Non-controlling interests (11) (9) Total equity (8,756) (7,503)	Other current liabilities	(1,160)	(1,028)
Non-current liabilities: (2,514) (2,374) Financial debt and other non-current liabilities (863) (753) Deferred tax liabilities (863) (753) Provisions (841) (968) Total non-current liabilities (4,218) (4,095) Total liabilities (10,645) (9,738) Equity: Shareholders' equity (8,745) (7,494) Non-controlling interests (11) (9) 1 Total equity (8,756) (7,503)	Provisions	(236)	(232)
Financial debt and other non-current liabilities $(2,514)$ $(2,374)$ Deferred tax liabilities (863) (753) Provisions (841) (968) Total non-current liabilities $(4,218)$ $(4,095)$ Total liabilities $(10,645)$ $(9,738)$ Equity:Shareholders' equity $(8,745)$ $(7,494)$ Non-controlling interests (11) (9) Total equity $(8,756)$ $(7,503)$	Total current liabilities	(6,427)	(5,643)
Deferred tax liabilities (863) (753) Provisions (841) (968) Total non-current liabilities (4,218) (4,095) Total liabilities (10,645) (9,738) Equity: Shareholders' equity Shareholders' equity (8,745) (7,494) Non-controlling interests (11) (9) Total equity (8,756) (7,503)	Non-current liabilities:		
Provisions (841) (968) Total non-current liabilities (4,218) (4,095) Total liabilities (10,645) (9,738) Equity: Shareholders' equity Shareholders' equity (8,745) (7,494) Non-controlling interests (11) (9) Total equity (8,756) (7,503)	Financial debt and other non-current liabilities	(2,514)	(2,374)
Total non-current liabilities (4,218) (4,095) Total liabilities (10,645) (9,738) Equity: (10,645) (7,494) Shareholders' equity (8,745) (7,494) Non-controlling interests (11) (9) Total equity (8,756) (7,503)	Deferred tax liabilities	(863)	(753)
Total liabilities (10,645) (9,738) Equity: (10,645) (7,494) Shareholders' equity (8,745) (7,494) Non-controlling interests (11) (9) Total equity (8,756) (7,503)	Provisions	(841)	(968)
Equity: (8,745) (7,494) Shareholders' equity (11) (9) Non-controlling interests (8,756) (7,503)	Total non-current liabilities	(4,218)	(4,095)
Shareholders' equity (8,745) (7,494) Non-controlling interests (11) (9) Total equity (8,756) (7,503)	Total liabilities	(10,645)	(9,738)
Non-controlling interests (11) (9) Total equity (8,756) (7,503)	Equity:		
Total equity (8,756) (7,503)	Shareholders' equity	(8,745)	(7,494)
	Non-controlling interests	(11)	(/
Total liabilities and equity(19,401)(17,241)	Total equity	(8,756)	(7,503)
	Total liabilities and equity	(19,401)	(17,241)

Syngenta – February 6, 2013/ 11 of 42

Condensed Consolidated Cash Flow Statement

For the year ended December 31,			
(\$m)	201	2	2011
Income before taxes	2,152		1,901
Reversal of non-cash items	984		801
Cash (paid)/received in respect of:			
Interest and other financial receipts	197		312
Interest and other financial payments	(422)	(426)
Income taxes	(378)	(282)
Restructuring costs	(55)	(71)
Contributions to pension plans, excluding restructuring costs	(78)	(198)
Other provisions	(182)	(116)
Cash flow before change in net working capital	2,218		1,921
Change in net working capital:			
Change in inventories	(555)	(478)
Change in trade and other working capital assets	(814)	(120)
Change in trade and other working capital liabilities	510		548
Cash flow from operating activities	1,359		1,871
Additions to property, plant and equipment	(508)	(479)
Proceeds from disposals of property, plant and equipment	30		20
Purchases of intangible assets	(112)	(62)
Purchases of investments in associates and other financial assets	(59)	(62) (34)
Proceeds from disposals of intangible and financial assets	21		22
Cash flow from (purchases)/disposals of marketable securities, net	(8)	11
Acquisitions and divestments, net	(582)	50
Cash flow used for investing activities	(1,218)	(472)
Increases in third party interest-bearing debt	1,256		305
Repayments of third party interest-bearing debt	(721)	(906)
(Purchases)/sales of treasury shares and options over own shares, net	24		(377)
Distributions paid to shareholders	(791)	(706)
Cash flow used for financing activities	(232)	(1,684)
Net effect of currency translation on cash and cash equivalents	24		(16)
Net change in cash and cash equivalents	(67)	(301)
Cash and cash equivalents at the beginning of the year	1,666		1,967
Cash and cash equivalents at the end of the year	1,599		1,666

Syngenta – February 6, 2013/ 12 of 42

Condensed Consolidated Statement of Changes in Equity

Attributable to Syngenta AG shareholders														
	Par													
	value		T			- ·	a				Total			
		dditional		•				mulativ			share-			
/ * \	ordinary	paid-in		shares,						Retained	holderon-		-	Total
(\$m)	shares	capital					ad	0	nt e	earnings	equity	intere	sts	equity
January 1, 2011	6	3,491		(489))	(36)	658		3,809	7,439	10		7,449
Net income										1,599	1,599	1		1,600
OCI						(113)	(233)	(181)	(527)	(1)	(528)
Total comprehensive														
income	-	-		-		(113)	(233)	1,418	1,072	-		1,072
Share based														
compensation				34						65	99			99
Dividends paid										(705)	(705)	(1)	(706)
Share repurchases				(422))						(422)			(422)
Cancellation of treasury	7													
shares		(31)	195						(164)	-			-
Other and income taxes														
on share based														
compensation										11	11			11
December 31, 2011	6	3,460		(682))	(149)	425		4,434	7,494	9		7,503
Net income										1,872	1,872	3		1,875
OCI														